The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Insulet met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP loss per share dropped.
Margins grew across the board.
Insulet recorded revenue of $54.8 million. The 16 analysts polled by S&P Capital IQ predicted sales of $54.9 million on the same basis. GAAP reported sales were 23% higher than the prior-year quarter's $44.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.26. The 14 earnings estimates compiled by S&P Capital IQ forecast -$0.22 per share. GAAP EPS were -$0.26 for Q3 compared to -$0.29 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 44.5%, 290 basis points better than the prior-year quarter. Operating margin was -15.5%, 640 basis points better than the prior-year quarter. Net margin was -22.7%, 770 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $60.0 million. On the bottom line, the average EPS estimate is -$0.17.
Next year's average estimate for revenue is $214.1 million. The average EPS estimate is -$0.99.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 68 members out of 111 rating the stock outperform, and 43 members rating it underperform. Among 40 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give Insulet a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $22.91.
- Add Insulet to My Watchlist.